MedPath

Kava

Generic Name
Kava
Drug Type
Small Molecule
Chemical Formula
C14H16O3
CAS Number
9000-38-8
Unique Ingredient Identifier
BOW48C81XP
Clinical Trials
Related News

Effect of Kava on Anxiety and Stress in Cancer Survivors

Early Phase 1
Recruiting
Conditions
Anxiety
Stress
Sleep
Kava
Cancer
Depression
Interventions
Dietary Supplement: Placebo
First Posted Date
2024-01-19
Last Posted Date
2025-03-18
Lead Sponsor
Masonic Cancer Center, University of Minnesota
Target Recruit Count
43
Registration Number
NCT06213298
Locations
🇺🇸

Masonic Cancer Center, Minneapolis, Minnesota, United States

The Potential of Kava in Enabling Tobacco Cessation - Its Holistic Effects in Managing Stress and Insomnia Associated With Abstinence

Phase 2
Recruiting
Conditions
Smoking
Interventions
Drug: Placebo
First Posted Date
2023-04-14
Last Posted Date
2025-02-05
Lead Sponsor
University of Florida
Target Recruit Count
76
Registration Number
NCT05814055
Locations
🇺🇸

University of Florida, Gainesville, Florida, United States

Reducing Tobacco-associated Lung Cancer Risk: A Randomized Clinical Trial of AB-free Kava

Phase 2
Suspended
Conditions
Smoking
Interventions
Drug: Placebo
First Posted Date
2021-10-18
Last Posted Date
2025-04-25
Lead Sponsor
University of Florida
Target Recruit Count
80
Registration Number
NCT05081882
Locations
🇺🇸

University of Florida, Gainesville, Florida, United States

Biomarker Changes and Anxiolytic Effects-Phase 2

Phase 2
Completed
Conditions
Pharmacokinetics
Interventions
Drug: Placebo
First Posted Date
2020-09-25
Last Posted Date
2024-08-13
Lead Sponsor
University of Florida
Target Recruit Count
39
Registration Number
NCT04565145
Locations
🇺🇸

UF CTSI Clinical Research Center, Gainesville, Florida, United States

A Phased Clinical Trial of Dietary Supplemental Kava: Kava Pharmacokinetics

Phase 1
Completed
Conditions
Pharmacokinetics
Interventions
First Posted Date
2019-02-18
Last Posted Date
2024-06-12
Lead Sponsor
University of Florida
Target Recruit Count
10
Registration Number
NCT03843502
Locations
🇺🇸

UF CTSI Clinical Research Center, Gainesville, Florida, United States

Exploring the Impact of Two-week Kava on the Metabolism of Nicotine and NNK

Phase 1
Withdrawn
Conditions
Kava on the Metabolism of Nicotine and NNK
Interventions
First Posted Date
2018-07-31
Last Posted Date
2020-01-13
Lead Sponsor
University of Florida
Registration Number
NCT03606655

Kava Kava for the Treatment of Generalized Anxiety Disorder (GAD)

Phase 2
Terminated
Conditions
Anxiety Disorders
Interventions
Drug: Sugar pill
First Posted Date
2004-06-07
Last Posted Date
2012-10-19
Lead Sponsor
National Center for Complementary and Integrative Health (NCCIH)
Target Recruit Count
16
Registration Number
NCT00083980

Effects of Kava on the Body's Elimination of Caffeine and Dextromethorphan

Phase 4
Completed
Conditions
Healthy
First Posted Date
2002-12-10
Last Posted Date
2008-03-04
Lead Sponsor
National Institutes of Health Clinical Center (CC)
Target Recruit Count
20
Registration Number
NCT00009542
Locations
🇺🇸

Warren G. Magnuson Clinical Center (CC), Bethesda, Maryland, United States

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy